Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Hemab Therapeutics Holdings, Inc. Common Stock

COAG

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Last trade $38.26
Day change -$0.795 (-2.04%)
Day range $37.51 – $41.51
Volume 144,212
Market cap $1.83B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.83B
Price / earnings
—
Price / book
4.25×
Price / sales
—
EV / sales
—
EV / EBITDA
-19.89×

Profitability

Earnings per share
-$1.59
Return on assets
-16.75%
Return on equity
-17.27%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
33.86×
Quick ratio
33.86×
Cash ratio
18.48×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$89.08M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for COAG, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026
Revenue$0$0
Cost of revenue$0$0
Gross profit$0$0
Selling, general and administrative$5.12M$5.74M
Research and development$24.64M$20.34M
Total operating expenses$30M$26.08M
Operating income-$30M-$26.08M
Interest expense$0$0
Income before taxes-$26.61M-$24.05M
Income taxes$693K$97K
Net income-$27.3M-$24.15M
Net income attributable to common shareholders-$27.3M-$24.15M
EBITDA-$29.92M-$26M
Basic earnings per share-$0.58-$0.80
Diluted earnings per share-$0.58-$0.80

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

Hemab Therapeutics presented clinical data from HMB-002 showing proof of mechanism in Von Willebrand disease, with dose-dependent increases in VWF and FVIII levels supporting potential monthly subcutaneous dosing. The company also announced HMB-003, a novel non-hormonal antifibrinolytic designed to treat heavy menstrual bleeding with extended duration of action.

Benzinga

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG), a clinical-stage biotechnology company focused on blood coagulation disorder treatments, successfully closed its IPO on May 4, 2026. The company raised approximately $346.7 million through the sale of 19,262,500 shares at $18.00 per share, with underwriters fully exercising their option to purchase an additional 2,512,500 shares. The company's stock began trading on Nasdaq on May 1, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.